Janux Therapeutics (JANX) Enterprise Value: 2020-2025
Historic Enterprise Value for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to $479.7 million.
- Janux Therapeutics' Enterprise Value fell 71.98% to $479.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.6 billion, marking a year-over-year decrease of 3765.66%. This contributed to the annual value of $1.8 billion for FY2024, which is 1079.12% up from last year.
- Janux Therapeutics' Enterprise Value amounted to $479.7 million in Q3 2025, which was up 29.32% from $370.9 million recorded in Q2 2025.
- In the past 5 years, Janux Therapeutics' Enterprise Value registered a high of $1.8 billion during Q4 2024, and its lowest value of $115.4 million during Q3 2023.
- Its 3-year average for Enterprise Value is $763.4 million, with a median of $479.7 million in 2025.
- As far as peak fluctuations go, Janux Therapeutics' Enterprise Value soared by 5,808.82% in 2021, and later slumped by 75.69% in 2025.
- Quarterly analysis of 5 years shows Janux Therapeutics' Enterprise Value stood at $446.0 million in 2021, then plummeted by 50.30% to $221.7 million in 2022, then crashed by 31.72% to $151.4 million in 2023, then skyrocketed by 1,079.12% to $1.8 billion in 2024, then tumbled by 71.98% to $479.7 million in 2025.
- Its Enterprise Value stands at $479.7 million for Q3 2025, versus $370.9 million for Q2 2025 and $581.7 million for Q1 2025.